Compare Dyne Therapeutics Inc. Common Stock (DYN) vs iShares Self-Driving EV and Tech (IDRV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs iShares Self-Driving EV and Tech — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.07 (market cap $2.86B), while iShares Self-Driving EV and Tech trades at $32 (market cap $258.76M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 11.1× iShares Self-Driving EV and Tech's market cap, and iShares Self-Driving EV and Tech is more actively traded (39,075 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and iShares Self-Driving EV and Tech for 75 Days on average.
| DYN | IDRV | |
|---|---|---|
Market Cap | $2.86B | $258.76M |
Volume | 3,341,579 | 39,075 |
Sector | Health | Sector/Thematic |
52-Week High | $26.78 | $45.48 |
52-Week Low | $14.60 | $32.18 |
Typical Hold Time | 0 Days | 75 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
IDRV trades at $32.78, up 0.43% on the day, with a bearish technical outlook as moving averages signal strong selling pressure. The stock faces headwinds from lukewarm US electric vehicle adoption despite global EV sales growth. Key support sits at $32 with resistance at $33-34 levels, while oscillators remain neutral suggesting potential consolidation.
The EV sector faces mixed signals with regulatory uncertainty and oil price volatility creating near-term challenges. Long-term prospects remain tied to global EV adoption trends, particularly in China and Europe where growth continues. Investors should weigh regulatory risks against the sector's structural growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →
